Vimarsana
Biggest News Aggregation in the World

Page 2 - Buzz Show News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Buzz Show. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Buzz Show Today - Breaking & Trending Today

"The Buzz" Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index | Financial Buzz"The Buzz'' Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index - Vimarsana News

"The Buzz" Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index | Financial Buzz"The Buzz'' Show: Bionano Genomics, Inc. (NASDAQ: BNGO) Joins US Small-Cap Russell 2000® Index

Posted on FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Bionano Genomics, Inc. up 6% after Becoming a Member of US Small-Cap Russell 2000® Index” Bionano Genomics, Inc. (NASDAQ: BNGO) gained over 6% in premarket trading after the Company said it was added as a member of the US small-cap Russell 2000® Index, effective as of the Market open on June 28th. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index, with the indexes widely u...

"The Buzz" Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data | Financial Buzz"The Buzz'' Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data - Vimarsana News

"The Buzz" Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data | Financial Buzz"The Buzz'' Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Intellia Therapeutics, Inc. Surges Following Positive Gene Editing Data” Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001. The Phase 1 study of a single-dose treatment for ATTR is evaluating the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for pre...

"The Buzz" Show: Clearside Biomedical, Inc. (NASDAQ: CLSD) Reports Positive Safety Results - Vimarsana News

"The Buzz" Show: Clearside Biomedical, Inc. (NASDAQ: CLSD) Reports Positive Safety Results

51 FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Clearside Biomedical, Inc. (NASDAQ: CLSD) Reports Positive Safety Results” Clearside Biomedical, Inc. (NASDAQ: CLSD) a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, reported Tuesday positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside...

"The Buzz" Show: Alfi, Inc. (NASDAQ: ALF) Agreement with All-Niter on Tablets to Uber and Lyft Drivers Nationwide - Vimarsana News

"The Buzz" Show: Alfi, Inc. (NASDAQ: ALF) Agreement with All-Niter on Tablets to Uber and Lyft Drivers Nationwide

Posted on 3 FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Alfi, Inc. (NASDAQ: ALF) Agreement with All-Niter on Tablets to Uber and Lyft Drivers Nationwide” Alfi, Inc. (NASDAQ: ALF), an AI enterprise SaaS platform company powering computer vision with machine learning models to allow content publishers and brand owners to deliver interactive, intelligent information without violating user privacy, announced on Tuesday that it has entered into an agreement with All-Niter for the fulfillment, ...

"The Buzz" Show: Iterum Therapeutics (NASDAQ: ITRM) Provides Update on FDA Review | Financial Buzz"The Buzz" Show: Iterum Therapeutics (NASDAQ: ITRM) Provides Update on FDA Review - Vimarsana News

"The Buzz" Show: Iterum Therapeutics (NASDAQ: ITRM) Provides Update on FDA Review | Financial Buzz"The Buzz" Show: Iterum Therapeutics (NASDAQ: ITRM) Provides Update on FDA Review

#post_contentFinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Iterum Therapeutics Surges Following FDA Late-Cycle Meeting”